Stocks
EYENET LIMITEDEYEN
HealthcareBiotechnology
A clinical-stage biopharmaceutical company developing targeted therapies for oncology, with a focus on a portfolio of small molecule drug candidates. Its lead programs address solid tumors and hematologic malignancies, and investor interest centers on upcoming clinical data readouts and the company's novel approach to kinase inhibition.
Congressional Interest in EYENET LIMITED (EYEN)
1 member of Congress has disclosed 1 trade in EYENET LIMITED (EYEN), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading EYEN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-05-04 | MICHAEL T. MCCAUL | sell | $1K-$15K |